Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2024)

Spero Therapeutics (SPRO) has disclosed Non-Current Debt for 6 consecutive years, with $13000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Debt fell 79.03% year-over-year to $13000.0, compared with a TTM value of $13000.0 through Sep 2024, down 79.03%, and an annual FY2023 reading of $87000.0, down 9.38% over the prior year.
  • Non-Current Debt was $13000.0 for Q3 2024 at Spero Therapeutics, down from $25000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $205000.0 in Q1 2020 and bottomed at $13000.0 in Q3 2024.
  • Average Non-Current Debt over 5 years is $116105.3, with a median of $117000.0 recorded in 2022.
  • The sharpest move saw Non-Current Debt dropped 9.38% in 2023, then tumbled 79.03% in 2024.
  • Year by year, Non-Current Debt stood at $177000.0 in 2020, then dropped by 22.03% to $138000.0 in 2021, then crashed by 30.43% to $96000.0 in 2022, then decreased by 9.38% to $87000.0 in 2023, then tumbled by 85.06% to $13000.0 in 2024.
  • Business Quant data shows Non-Current Debt for SPRO at $13000.0 in Q3 2024, $25000.0 in Q2 2024, and $38000.0 in Q1 2024.